elEconomista

SIR-Spheres® microspheres as Effective and Safe in the Elderly as they are in Younger Patients with Colorectal Liver Metastases According to Data Released at ASCO Annual Meeting

According to investigators, the use of SIR-Spheres microspheres in elderly patients with unresectable colorectal liver metastases (mCRC) appears to be as effective and well-tolerated as in younger ...
Cure Today

FDA Approves SIR-Spheres for Liver Cancer Treatment

SIR-Spheres® Y-90 resin microspheres are now FDA-approved for unresectable HCC, marking a unique approval for both HCC and mCRC in the U.S. The DOORwaY90 study showed a 98.5% overall response rate and ...
Business Insider

NASIR-HCC: Phase 2 study of Sirtex Medical SIR-Spheres® Y-90 resin microspheres followed by Nivolumab therapy demonstrates favorable safety and tolerability profile at ILCA 2020

WOBURN, Mass., Sept. 14, 2020 /CNW/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapy, SIR-Spheres® Y-90 resin microspheres, is pleased to report that positive ...
Business Insider

DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient

First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres ® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /CNW/ -- Sirtex ...
Healio

FDA approves SIR-Spheres for unresectable hepatocellular carcinoma

Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...
ascopubs.org

Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The ...
ascopubs.org

A phase I study of capecitabine in combination with yttrium-90 labeled resin microspheres (SIR-Spheres) in patients (pts) with advanced cancer.

Phase II study with docetaxel (D), cisplatin (C), and continuous capecitabine (CAP) combination (TCX) in advanced gastric cancer: Preliminary data. This is an ASCO Meeting Abstract from the 2011 ASCO ...
TASS

Sirtex Medical reaches milestone 100,000th patient dose delivery microspheres

WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y ...
Yahoo Finance

Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

WOBURN, Mass., April 13, 2026 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from ...
Wane

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...